Literature DB >> 18496272

The effect of aortic valve incompetence on the hemodynamics of a continuous flow ventricular assist device in a mock circulation.

Mario A Zamarripa Garcia1, Luz A Enriquez, Walter Dembitsky, Karen May-Newman.   

Abstract

There is evidence that the incidence of aortic valve incompetence (AI) and other valvular pathologies may increase as more patients are submitted to longer periods of ventricular assist device (VAD) support. There is a need to better understand the mechanisms associated with the onset of these conditions and other possible complications related to the altered hemodynamics of VAD patients. In this study, the effect of AI on the hemodynamic response of continuous flow VAD (C-VAD) patients was measured in a mock loop over a range of pump speeds and level of native cardiac function. Our results showed that, in the presence of sufficient ventricular function, decreasing the C-VAD speed can allow a transition from series to parallel flow. Our study demonstrated that AI reduces the aortic pressure and flow when system impedance is unchanged. AI produces wasteful recirculation that substantially increases the pump work and decreases systemic perfusion, in particular during series flow conditions coupled with higher C-VAD speeds. The hematologic consequence of this regurgitant flow is a much higher exposure to shear for the blood, increasing the likelihood of hemolysis and thrombosis. While a certain degree of AI can be tolerated by a heart with good cardiac function, the consequences of AI for patients with VADs and poor cardiac function are much greater. Valve dysfunction in VAD patients may be related to structural changes in the tissue induced by altered biomechanics and excessive stress.

Entities:  

Mesh:

Year:  2008        PMID: 18496272     DOI: 10.1097/MAT.0b013e31816a309b

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  6 in total

Review 1.  Management of aortic insufficiency in the continuous flow left ventricular assist device population.

Authors:  Jonathan Holtz; Jeffrey Teuteberg
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 2.  Review of recent results using computational fluid dynamics simulations in patients receiving mechanical assist devices for end-stage heart failure.

Authors:  Mina Berty Farag; Christof Karmonik; Fabian Rengier; Matthias Loebe; Matthias Karck; Hendrik von Tengg-Kobligk; Arjang Ruhparwar; Sasan Partovi
Journal:  Methodist Debakey Cardiovasc J       Date:  2014 Jul-Sep

3.  Design and execution of a verification, validation, and uncertainty quantification plan for a numerical model of left ventricular flow after LVAD implantation.

Authors:  Alfonso Santiago; Constantine Butakoff; Beatriz Eguzkitza; Richard A Gray; Karen May-Newman; Pras Pathmanathan; Vi Vu; Mariano Vázquez
Journal:  PLoS Comput Biol       Date:  2022-06-13       Impact factor: 4.779

4.  Establishment of a Modular Hemodynamic Simulator for Accurate In Vitro Simulation of Physiological and Pathological Pressure Waveforms in Native and Bioartificial Blood Vessels.

Authors:  Florian Helms; Axel Haverich; Mathias Wilhelmi; Ulrike Böer
Journal:  Cardiovasc Eng Technol       Date:  2021-09-23       Impact factor: 2.305

5.  Left ventricular outflow tract closure during LVAD implantation: 2 cases of patients supported for over 6 years.

Authors:  Andre Critsinelis; Chitaru Kurihara; Masashi Kawabori; Tadahisa Sugiura; Andrew B Civitello; O H Frazier; Jeffrey A Morgan
Journal:  J Artif Organs       Date:  2017-10-05       Impact factor: 1.731

6.  Protracted aortic valve closure during peripheral veno-arterial extracorporeal life support: is intra-aortic balloon pump an effective solution?

Authors:  Paolo Meani; Thijs Delnoij; Giuseppe M Raffa; Nuccia Morici; Giovanna Viola; Alice Sacco; Fabrizio Oliva; Sam Heuts; Jan-Willem Sels; Rob Driessen; Paul Roekaerts; Martijn Gilbers; Elham Bidar; Rick Schreurs; Ehsan Natour; Leo Veenstra; Suzanne Kats; Jos Maessen; Roberto Lorusso
Journal:  Perfusion       Date:  2018-07-19       Impact factor: 1.972

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.